Out-of-pocket costs for contemporary advanced prostate cancer care in commercially insured patients

Financial toxicity, including the burden of out-of-pocket expenses, can negatively affect patients’ decision to seek care. Here, researchers examined what influences a patient’s ability to pay for advanced treatments for advanced prostate cancer. Men with advanced prostate cancer who were treated by commercial insurers between 2007 and 2019 were located using the OptumLabs Data Warehouse®. Treatment options for these patients included androgen deprivation monotherapy, new hormone therapy, and systemic non-androgen therapy. The patient’s financial responsibility for medical care during the first year of treatment was the primary measure. Multivariate regression models were used to analyze associations between therapy and patient-related factors and out-of-pocket expenses. With the help of the Consumer Price Index CPI, all prices were updated to 2019 US dollars. The majority of the 13,409 men in the study group were treated with monotherapy of androgen deprivation (n=10,926), while only 6% (n=832) received new hormone therapy and 12% (n=1,651) received non-androgen systemic therapy. . Patients who chose androgen deprivation monotherapy spent an average of $165 in medical costs in the first year, while those who opted for new hormone therapy spent $4,236 and those who opted for systemic therapy not androgenic spent $994. Systemic non-androgen therapy and new hormone therapy both had adjusted annual out-of-pocket costs of $752 (95% CI: $600 to $903) and $2,581 (95% CI: $1,923 to 3, respectively). $240) higher than androgen deprivation monotherapy. Older age (65 to 74), black race, lower comorbidity scores, and lower family income were also correlated patient variables (P

Source: auajournals.org/doi/full/10.1097/JU.0000000000002856

Comments are closed.